LegoChem Biosciences, Inc., a leading South Korean antibody-drug conjugate (ADC) platform company in the news recently for a major alliance, has generated more headlines through a surprise shareholding tie-up with a major domestic confectionery group, through which it will raise KRW548.5bn ($413m).
ADC Specialist LegoChem Takes Orion’s Hand As Long-Term Partner
26% Stake Should Ensure Competitive R&D
Korean confectionery group Orion has become the biggest shareholder in compatriot ADC specialist LegoChem Biosciences, in a decisive step to move into the biotech sector as a new growth engine. For LegoChem, the alliance provides a friendly strategic partner and should enable a boost in R&D spending as it seeks to aggressively progress clinical trials and become a global player.

More from South Korea
More from Focus On Asia
Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process
Lilly’s Mounjaro arrives in India, with the 2.5mg vial priced at under $41 in a market that has over 100 million diabetics and increasing obesity rates. Will the product see sharp demand like in China, carving out a chunk of the pie ahead of the potential arrival of semaglutide generics and could there be concerns of ‘suitcase' exports?
South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.